Burns GC, Catala A, Paul S, Matute R, Onyema D, Toth I, Saha DC
Response to early and prolonged inhibition of angiotensin converting enzyme in HIV-associated nephropathy
Am Soc Nephrol
J Am Soc Nephrol (abstract) (Nov) 6:414 1995

Three biopsy-proven patients with HIV-Associated nephropathy (HIVAN) received fosinopril 10 mg daily and compared to 4 control patients. Baseline characteristics were similar in the treated and control patients (Serum creatinine 1.5 vs. 1.0, 24 hour protein 1.5 vs 0.7 grams). All treated patients remained stable, while all control patients doubled their creatinine within 6 months and became azotemic and nephrotic; differences were statistically significant. By 12 months control patients required dialysis. It was not clear how the control patients were selected, whether they were biopsied and what other medications they received. Furthermore this study did not appear to be randomized. Nevertheless, the conclusion that ACEI's may prevent or delay the development of nephrotic syndrome and progressive renal failure in selected patients with HIVAN is strongly suggested, and further formal study warranted. (Pastan)

To go back use the BACK button on your browser.
Otherwise click on the desired link to this article below:
Am Soc Nephrol
Proteinuria/Hematuria : HIV-associated nephropathy